Commerce Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,137
| Closed | -$222K | – | 1192 |
|
|
2025
Q1 | $222K | Buy |
+3,137
| New | +$211K | ﹤0.01% | 1109 |
|
|
2024
Q4 | – | Sell |
-4,707
| Closed | -$331K | – | 1183 |
|
|
2024
Q3 | $331K | Sell |
4,707
-3,949
| -46% | -$330K | ﹤0.01% | 1028 |
|
|
2024
Q2 | $713K | Sell |
8,656
-34,131
| -80% | -$2.84M | ﹤0.01% | 729 |
|
|
2024
Q1 | $3.74M | Buy |
42,787
+6,218
| +17% | +$557K | 0.02% | 380 |
|
|
2023
Q4 | $3.53M | Sell |
36,569
-3,050
| -8% | -$270K | 0.03% | 371 |
|
|
2023
Q3 | $3.51M | Sell |
39,619
-139
| -0.3% | -$12.4K | 0.03% | 346 |
|
|
2023
Q2 | $3.45M | Buy |
39,758
+34,559
| +665% | +$3.25M | 0.03% | 360 |
|
|
2023
Q1 | $506K | Buy |
5,199
+627
| +14% | +$65K | ﹤0.01% | 802 |
|
|
2022
Q4 | $473K | Sell |
4,572
-41
| -0.9% | -$3.85K | ﹤0.01% | 819 |
|
|
2022
Q3 | $391K | Buy |
4,613
+79
| +2% | +$7.03K | ﹤0.01% | 861 |
|
|
2022
Q2 | $376K | Sell |
4,534
-885
| -16% | -$70.5K | ﹤0.01% | 872 |
|
|
2022
Q1 | $418K | Buy |
5,419
+198
| +4% | +$16.6K | ﹤0.01% | 887 |
|
|
2021
Q4 | $461K | Buy |
5,221
+685
| +15% | +$56.5K | ﹤0.01% | 879 |
|
|
2021
Q3 | $351K | Sell |
4,536
-2,624
| -37% | -$207K | ﹤0.01% | 958 |
|
|
2021
Q2 | $597K | Sell |
7,160
-348
| -5% | -$27.6K | ﹤0.01% | 769 |
|
|
2021
Q1 | $567K | Buy |
7,508
+515
| +7% | +$42.1K | ﹤0.01% | 764 |
|
|
2020
Q4 | $613K | Buy |
6,993
+613
| +10% | +$48.6K | 0.01% | 703 |
|
|
2020
Q3 | $485K | Buy |
6,380
+1,284
| +25% | +$130K | ﹤0.01% | 695 |
|
|
2020
Q2 | $629K | Buy |
5,096
+1,155
| +29% | +$115K | 0.01% | 603 |
|
|
2020
Q1 | $333K | Buy |
3,941
+439
| +13% | +$37.8K | ﹤0.01% | 721 |
|
|
2019
Q4 | $296K | Sell |
3,502
-39,993
| -92% | -$3.02M | ﹤0.01% | 830 |
|
|
2019
Q3 | $2.93M | Buy |
43,495
+36,064
| +485% | +$2.78M | 0.03% | 339 |
|
|
2019
Q2 | $637K | Buy |
7,431
+388
| +6% | +$33.2K | 0.01% | 539 |
|
|
2019
Q1 | $626K | Sell |
7,043
-134
| -2% | -$12.4K | 0.01% | 507 |
|
|
2018
Q4 | $611K | Buy |
7,177
+3,574
| +99% | +$340K | 0.01% | 480 |
|
|
2018
Q3 | $349K | Buy |
3,603
+417
| +13% | +$41.6K | ﹤0.01% | 695 |
|
|
2018
Q2 | $300K | Buy |
+3,186
| New | +$279K | ﹤0.01% | 722 |
|
|
2018
Q1 | – | Sell |
-2,907
| Closed | -$259K | – | 842 |
|
|
2017
Q4 | $259K | Buy |
2,907
+662
| +29% | +$57.6K | ﹤0.01% | 754 |
|
|
2017
Q3 | $209K | Buy |
+2,245
| New | +$198K | ﹤0.01% | 789 |
|
Other funds holding BMRN
Commerce Bank's BMRN Position: Q2 2025 in Review
Commerce Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 3,137 shares — an estimated $222K sold.
Commerce Bank first reported a position in BMRN in Q3 2017 and held it in 29 quarters. The position peaked at $3.74M in Q1 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.
- Commerce Bank reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
- Commerce Bank sold 3,137 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $222K.
- Commerce Bank first reported a position in BioMarin Pharmaceuticals in Q3 2017 and held it in 29 quarters.
- Commerce Bank's BioMarin Pharmaceuticals position peaked at $3.74M in Q1 2024.
- 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.
Based on Commerce Bank's 13F filing for Q2 2025, filed 7 Aug 2025.